Our mission is to liberate autoimmune patients through the curative potential of cell therapy.
A new era of CAR T-cell therapy
Kyverna is pioneering a durable disease-clearing approach aiming for deep B cell depletion, an immune system reset, and long-term remission in autoimmune diseases.
Bringing the transformational experience of cell therapies to autoimmune diseases
We believe the success of CAR T-cell therapies in B cell-driven hematological malignancies can be leveraged to deliver therapeutic benefits in patients living with autoimmune diseases.
A patient-centric approach
We are a patient-centered, clinical-stage biopharmaceutical company with active, ongoing clinical trials for multiple autoimmune diseases at different locations across the world.
How does CAR T-cell therapy work?
Cell therapy holds the potential to reset the immune system after a single infusion, aimed at achieving long-lasting, treatment-free remission.
01: Patient’s blood is collected and white blood cells (including T cells) are separated.
02: T cells are altered so that they can recognize, attack, and destroy the B cells.
03: Altered T cells are returned back to the patient via an intravenous infusion.
04: The CAR T cells attack B cells, including unhealthy B cells with the goal of helping to control, reduce, or reverse the disease.
05: The aim is for the body to replenish with its own healthy B cells.
Clinical trials
Participation in clinical trials is the best way to access our investigational product. Kyverna may consider requests for expanded access when alternative therapy options have been exhausted.